Resources for Genetics Professionals — Genetic Disorders Associated with Founder Variants Common in the Navajo Population
Stephanie E Wallace, MD and Lora JH Bean, PhD.
Author Information and AffiliationsInitial Posting: June 27, 2019; Last Revision: November 3, 2022.
Estimated reading time: 2 minutes
A founder variant is a pathogenic variant observed at high frequency in a specific population due to the presence of the variant in a single ancestor or small number of ancestors. The presence of a founder variant can affect the approach to molecular genetic testing. When one or more founder variants account for a large percentage of all pathogenic variants found in a population, testing for the founder variant(s) may be performed first. The table below includes common founder variants – here defined as three or fewer variants that account for >50% of the pathogenic variants identified in a single gene in individuals of a specific ancestry – in individuals of Navajo ancestry. Note: Pathogenic variants that are common worldwide due to a DNA sequence hot spot are not considered founder variants and thus are not included.
Table.
Genetic Disorders Associated with Founder Variants Common in the Navajo Population
View in own window
Included if ≤3 pathogenic variants account for ≥50% of variants identified in a specific ethnic group
AR = autosomal recessive; MOI = mode of inheritance
- 1.
Does not conform to standard HGVS nomenclature
- 2.
Percentage does not account for the possibility of rare de novo pathogenic variants occurring in this population.
- 3.
To date, additional pathogenic variants in this gene have not been reported in individuals of Navajo descent.
- 4.
Calculated carrier frequency based on the incidence of the disorder in individuals of Navajo ancestry; estimated carrier frequency is not based on molecular testing of the population.
References
Bitting CP, Hanson JA. Navajo neurohepatopathy: a case report and literature review emphasizing clinicopathologic diagnosis.
Acta Gastroenterol Belg. 2016;79:463–9. [
PubMed: 28209105]
Clericuzio C, Harutyunyan K, Jin W, Erickson RP, Irvine AD, McLean WH, Wen Y, Bagatell R, Griffin TA, Shwayder TA, Plon SE, Wang LL. Identification of a novel C16orf57 mutation in Athabaskan patients with poikiloderma with neutropenia.
Am J Med Genet A. 2011;155A:337–42. [
PMC free article: PMC3069503] [
PubMed: 21271650]
Holve S, Friedman B, Hoyme HE, Tarby TJ, Johnstone SJ, Erickson RP, Clericuzio CL, Cunniff C. Athabascan brainstem dysgenesis syndrome.
Am J Med Genet A. 2003;120A:169–73. [
PubMed: 12833395]
Holve S, Hu D, McCandless SE. Metachromatic leukodystrophy in the Navajo: fallout of the American-Indian Wars of the nineteenth century.
Am J Med Genet. 2001;101:203–8. [
PubMed: 11424134]
Karadimas CL, Vu TH, Holve SA, Chronopoulou P, Quinzii C, Johnsen SD, Kurth J, Eggers E, Palenzuela L, Tanji K, Bonilla E, De Vivo DC, DiMauro S, Hirano M. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene.
Am J Hum Genet. 2006;79:544–8. [
PMC free article: PMC1559552] [
PubMed: 16909392]
Kwan A, Hu D, Song M, Gomes H, Brown DR, Bourque T, Gonzalez-Espinosa D, Lin Z, Cowan MJ, Puck JM. Successful newborn screening for SCID in the Navajo Nation.
Clin Immunol. 2015;158:29–34. [
PMC free article: PMC4420660] [
PubMed: 25762520]
Pastor-Soler NM, Rafi MA, Hoffman JD, Hu D, Wenger DA. Metachromatic leukodystrophy in the Navajo Indian population: a splice site mutation in intron 4 of the arylsulfatase A gene.
Hum Mutat. 1994;4:199–207. [
PubMed: 7833949]
Schlegel C, Weis VG, Knowles BC, Lapierre LA, Martin MG, Dickman P, Goldenring JR, Shub MD. Apical Membrane Alterations in Non-intestinal Organs in Microvillus Inclusion Disease.
Dig Dis Sci. 2018;63:356–65. [
PMC free article: PMC5797493] [
PubMed: 29218485]
Tischfield MA, Bosley TM, Salih MA, Alorainy IA, Sener EC, Nester MJ, Oystreck DT, Chan WM, Andrews C, Erickson RP, Engle EC. Homozygous HOXA1 mutations disrupt human brainstem, inner ear, cardiovascular and cognitive development.
Nat Genet. 2005;37:1035–7. [
PubMed: 16155570]
Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease.
N Engl J Med. 2002;347:175–84. [
PubMed: 12124406]
Yi Z, Garrison N, Cohen-Barak O, Karafet TM, King RA, Erickson RP, Hammer MF, Brilliant MH. A. 122.5-kilobase deletion of the P gene underlies the high prevalence of oculocutaneous albinism type 2 in the Navajo population.
Am J Hum Genet. 2003;72:62–72. [
PMC free article: PMC420013] [
PubMed: 12469324]
